Abstract
Direct oral anticoagulants (DOACs) such as apixaban, dabigatran, edoxaban, and rivaroxaban are mainlyused in the prevention of thromboembolic complications in patients with atrial fibrillation (AF) and inthe treatment of venous thromboembolism. As compared with vitamin K antagonists (VKAs), they arecharacterized by at least similar efficacy and better safety profiles, especially with respect to intracranialhemorrhages. Moreover, they are more convenient therapeutic agents. The 2016 European Society ofCardiology guidelines clearly favor DOACs over VKAs in patients with AF. However, DOAC therapy isalso associated with the risk of bleeding complications. The aim of this review was to provide recommendationsfor the management of bleeding complications during DOAC therapy in the Polish setting.The recommendations were based on the most important documents concerning this issue and weredeveloped by representatives of different medical specialties. Experience in managing cases of bleedingon DOAC therapy is still limited. Therefore, we hope that this publication will be helpful in everyday clinicalpractice and that it will be useful for developing in‑hospitalrecommendations for the managementof patients with DOAC‑relatedbleeding.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
